Now approved to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A. Learn more here
Molybdenum cofactor deficiency (MoCD) Type A: rare and devastating, so urgent diagnosis is crucial
Be ready to take
action immediately
The impact of MoCD Type A on newborns and their families can be profound and prolonged. Identifying MoCD Type A early can be the first step in making a difference in the lives of these newborns and their families.
MoCD is a rare neurological disorder in newborns that can lead to severe brain toxicity, developmental delays, and death.1 Symptoms such as intractable seizures often appear within hours to days following birth.1-3 Progression is rapid, so clinicians need to take action as soon as symptoms occur.4,5
Origin believes that a rare disorder like MoCD deserves focus and commitment just like more common life-threatening diseases. We are using our unique expertise and specialized resources to alert clinicians about MoCD Type A and give them the material to diagnose it as early as possible. Dedicated to bringing timely therapy to children born with MoCD Type A, we have developed a novel substrate replacement therapy that is the first of its kind approved by the FDA.6
- Mechler K et al. Genet Med. 2015;17(12):965-970.
- Veldman A et al. Pediatrics. 2010;125(5):e1249-e1254.
- Schwahn BC et al. Lancet. 2015;386(10007):1955-1963.
- Durmaz MS et al. Radiol Case Rep. 2018;13(3):592-595.
- Zaki MS et al. Eur J Paediatr Neurol. 2016;20(5):714-722.
- NULIBRY [prescribing information]. Boston, MA: Origin Biosciences, Inc.; February 2021.
